Alyeska Investment Group
VBIV

Alyeska Investment Group’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Alyeska Investment Group’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-782,000
Closed -$516K – 733
2024
Q2 		$516K Hold
782,000
– – ﹤0.01% 503
2024
Q1 		$471K Hold
782,000
– – ﹤0.01% 431
2023
Q4 		$459K Hold
782,000
– – ﹤0.01% 438
2023
Q3 		$521K Buy
+782,000
New +$958K ﹤0.01% 446

Alyeska Investment Group's VBIV Position: Q3 2024 in Review

Alyeska Investment Group sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2024, closing a stake of 608,604 shares — an estimated $402K sold.

Alyeska Investment Group first reported a position in VBIV in Q3 2019 and held it in 6 quarters. The position peaked at $746K in Q3 2019. 1 fund tracked by Wall St. Rank holds VBIV as of Q3 2024.

  • Alyeska Investment Group reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2024 after selling out during the quarter.
  • Alyeska Investment Group sold 608,604 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2024, an estimated $402K.
  • Alyeska Investment Group first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q3 2019 and held it in 6 quarters.
  • Alyeska Investment Group's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $746K in Q3 2019.
  • 1 fund tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2024.

Based on Alyeska Investment Group's 13F filing for Q3 2024, filed 14 Nov 2024.